LncRNA KCNQ1OT1在DLBCL患者中的表达及其临床意义
|
摘要
目的 :探讨长链非编码RNA(long non-coding RNA,LncRNA )KCNQ1重叠转录物1(KCNQ1 overlapping transcript 1,KCNQ1OT1)在弥漫大B细胞淋巴瘤(di use large B cell lymphoma,DLBCL)患者外周血中的表达及其临床意义。方法 :采用实时荧光定量PCR法检测120例DLBCL患者和55例非肿瘤患者(作为对照组)血清中LncRNA KCNQ1OT1的表达,分析其与DLBCL患者临床病理特征及预后的关系。结果 :DLBCL患者血清中LncRNA KCNQ1OT1的表达水平显著高于对照组(P <0.001)。LncRNA KCNQ1OT1的表达与肿瘤大小、Ann Arbor分期、B症状、化疗敏感性及淋巴瘤国际预后指数(international prognostic index,IPI)均有关(P值均<0.001)。LncRNA KCNQ1OT1高表达的DLBCL患者无进展生存及总生存时间较低表达者均明显缩短(P值均<0.001)。Ann Arbor分期、LncRNA KCNQ1OT1表达、淋巴瘤IPI及化疗敏感性是DLBCL患者预后的独立影响因素(P值均<0.01)。结论:LncRNA KCNQ1OT1在DLBCL患者外周血中高表达,并且是DLBCL患者预后的独立影响因素。
Objective: To investigate the expression of long non-coding RNA(LncRNA) KCNQ1 overlapping transcript 1(KCNQ1OT1) in the peripheral blood of patients with diffuse large B-cell lymphoma(DLBCL), and to analyze its clinical significance.Methods: The expression of LncRNA KCNQ1OT1 in the serum samples of 120 DLBCL patients and 55 non-tumor patients(as the control group) was detected by real-time fluorescent quantitative PCR. The correlations of LncRNA KCNQ1OT1 expression with the clinicopathological features and prognosis of DLBCL patients were analyzed. Results: The expression level of LncRNA KCNQ1OT1 in the serum of DLBCL patients was higher than that in the control group(P < 0.001). The expression of LncRNA KCNQ1OT1 was correlated with the tumor size, Ann Arbor stage, B symptoms, chemosensitivity and the international prognostic index(IPI)(all P < 0.001). The progression-free survival(PFS) time and the overall survival(OS) time of DLBCL patients with LncRNA KCNQ1OT1 high expression were significantly shorter than those with LncRNA KCNQ1OT1 low expression(both P < 0.001). Ann Arbor stage, LncRNA KCNQ1OT1 expression, IPI and chemosensitivity were the independent prognosis factors for DLBCL patients(all P < 0.01).Conclusion: LncRNA KCNQ1OT1 is highly expressed in the serum of patients with DLBCL, and is one of independent prognosis factors for DLBCL patients.
Objective: To investigate the expression of long non-coding RNA(LncRNA) KCNQ1 overlapping transcript 1(KCNQ1OT1) in the peripheral blood of patients with diffuse large B-cell lymphoma(DLBCL), and to analyze its clinical significance.Methods: The expression of LncRNA KCNQ1OT1 in the serum samples of 120 DLBCL patients and 55 non-tumor patients(as the control group) was detected by real-time fluorescent quantitative PCR. The correlations of LncRNA KCNQ1OT1 expression with the clinicopathological features and prognosis of DLBCL patients were analyzed. Results: The expression level of LncRNA KCNQ1OT1 in the serum of DLBCL patients was higher than that in the control group(P < 0.001). The expression of LncRNA KCNQ1OT1 was correlated with the tumor size, Ann Arbor stage, B symptoms, chemosensitivity and the international prognostic index(IPI)(all P < 0.001). The progression-free survival(PFS) time and the overall survival(OS) time of DLBCL patients with LncRNA KCNQ1OT1 high expression were significantly shorter than those with LncRNA KCNQ1OT1 low expression(both P < 0.001). Ann Arbor stage, LncRNA KCNQ1OT1 expression, IPI and chemosensitivity were the independent prognosis factors for DLBCL patients(all P < 0.01).Conclusion: LncRNA KCNQ1OT1 is highly expressed in the serum of patients with DLBCL, and is one of independent prognosis factors for DLBCL patients.
引文
[1]BARNES JA,REDD R,FISHER DC,et al.Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma:Results of a phaseⅡstudy[J].Hematol Oncol,2018,1(8):110-115.
[2]CHAPUY B,STEWART C,DUNFORDAJ,et al.Author correction:molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes[J].Nat Med,2018,24(8):1290-1291.
[3]CHEN H,XUE YN,XIN CM,et al.Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma with Hodgkin/reed-sternberg-like cells in a patient with angioimmunoblastic T-cell lymphoma[J].Acta Derm Venereol,2018,5(1):179-186.
[4]GAMAGEK KK,RIFATHM IM,FERNANDO H.Migratory polyarthritis as a paraneoplastic syndrome in a patient with diffuse large Bcell lymphoma:a case report[J].J Med Case Rep,2018,12(1):189.
[5]HUNTINGTON S,KESHISHIAN A,MCGUIREM,et al.Costs of relapsed diffuse large B-cell lymphoma among Medicare patients[J].Leuk Lymphoma,2018,25(1):1-8.
[6]MOU K,LIU B,DING M,et al.LncRNA-ATBfunctions as a competing endogenous RNA to promote YAP1 by sponging miR-590-5p in malignant melanoma[J].Int JOncol,2018,53(3):1094-1104.
[7]WANG YD,SUN XJ,YIN JJ,et al.Long noncoding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma[J].Biomed Pharmacother,2018,106:134-141.
[8]XIA H,JING H,LI Y,et al.Long noncoding RNA HOXD-AS1 promotes non-small cell lung cancer migration and invasion through regulating miR-133b/MMP9axis[J].Biomed Pharmacother,2018,106:156-162.
[9]ZHANG L,CAO Y,WEI M,et al.Long noncoding RNA-RNCR3 overexpression deleteriously affects the growth of glioblastoma cells through miR-185-5p/Krüppel-like factor 16 axis[J].J Cell Biochem,2018,10(4):137-146.
[10]RUTHERFORD SC,LEONARD JP.DLBCL cell of origin:what role should it play in care today?[J].Oncology(Williston Park),2018,32(9):445-449.
[11]RECASENS-ZORZO C,CARDESA-SALZMANN T,PETAZZI P,et al.Pharmacological modulation of CXCR4cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma[J].Haematologica,2018,11(5):270-276.
[12]SHATKIN S,SHATKIN M,SMITH K,et al.Diffuse large B-cell lymphoma occurring with rhinophyma:a case report[J].Cureus,2018,10(4):e2536.
[13]李梅芳,杨瑜,陈道光,等.ICE方案挽救治疗52例复发难治性DLBCL的疗效及预后因素[J].肿瘤,2016,36(11):1376-1382.
[14]AMIN AD,PETERS TL,LI L,et al.Diffuse large B-cell lymphoma:can genomics improve treatment options for a curable cancer?[J]Cold Spring Harb Mol Case Stud,2017,3(3):a001719.
[15]CUBO AM,SOTO ZM,CRUZ MA,et al.Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone:A case report[J].Medicine(Baltimore),2017,96(19):e6846.
[16]YAMAMOTO M,WATANABE K,FUKUDAT,et al.Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy:A singleinstitution study[J].Anticancer Res,2017,37(5):2655-2662.
[17]LIU D,WU N,SUN H,et al.ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP[J].Oncotarget,2017,8(35):58292-58303.
[18]CHEN ZP,WEI JC,WANG Q,et al.Long noncoding RNA 00152 functions as a competing endogenous RNA to regulate NRP1 expression by sponging with mi RNA206 in colorectal cancer[J].Int JOncol,2018,53(3):1227-1236.
[19]JING N,HUANG T,GUO H,et al.LncRNACASC15 promotes colon cancer cell proliferation and metastasis by regulating the miR4310/LGR5/Wnt/β-catenin signaling pathway[J].Mol Med Rep,2018,18(2):2269-2276.
[20]GONG W,ZHENG J,LIU X,et al.Knockdown of long non-coding RNA KCNQ1OT1restrained glioma cells’malignancy by activating miR-370/CCNE2 axis[J].Front Cell Neurosci,2017,11:84.
[21]SUNAMURA N,OHIRA T,KATAOKA M,et al.Regulation of functional KCNQ1OT1 lnc RNA by beta-catenin[J].Sci Rep,2016,6:20690.
[22]LI C,MIAO R,ZHANG J,et al.Long noncoding RNA KCNQ1OT1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504[J].Int J Oncol,2018,3(13):122-127.
[2]CHAPUY B,STEWART C,DUNFORDAJ,et al.Author correction:molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes[J].Nat Med,2018,24(8):1290-1291.
[3]CHEN H,XUE YN,XIN CM,et al.Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma with Hodgkin/reed-sternberg-like cells in a patient with angioimmunoblastic T-cell lymphoma[J].Acta Derm Venereol,2018,5(1):179-186.
[4]GAMAGEK KK,RIFATHM IM,FERNANDO H.Migratory polyarthritis as a paraneoplastic syndrome in a patient with diffuse large Bcell lymphoma:a case report[J].J Med Case Rep,2018,12(1):189.
[5]HUNTINGTON S,KESHISHIAN A,MCGUIREM,et al.Costs of relapsed diffuse large B-cell lymphoma among Medicare patients[J].Leuk Lymphoma,2018,25(1):1-8.
[6]MOU K,LIU B,DING M,et al.LncRNA-ATBfunctions as a competing endogenous RNA to promote YAP1 by sponging miR-590-5p in malignant melanoma[J].Int JOncol,2018,53(3):1094-1104.
[7]WANG YD,SUN XJ,YIN JJ,et al.Long noncoding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma[J].Biomed Pharmacother,2018,106:134-141.
[8]XIA H,JING H,LI Y,et al.Long noncoding RNA HOXD-AS1 promotes non-small cell lung cancer migration and invasion through regulating miR-133b/MMP9axis[J].Biomed Pharmacother,2018,106:156-162.
[9]ZHANG L,CAO Y,WEI M,et al.Long noncoding RNA-RNCR3 overexpression deleteriously affects the growth of glioblastoma cells through miR-185-5p/Krüppel-like factor 16 axis[J].J Cell Biochem,2018,10(4):137-146.
[10]RUTHERFORD SC,LEONARD JP.DLBCL cell of origin:what role should it play in care today?[J].Oncology(Williston Park),2018,32(9):445-449.
[11]RECASENS-ZORZO C,CARDESA-SALZMANN T,PETAZZI P,et al.Pharmacological modulation of CXCR4cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma[J].Haematologica,2018,11(5):270-276.
[12]SHATKIN S,SHATKIN M,SMITH K,et al.Diffuse large B-cell lymphoma occurring with rhinophyma:a case report[J].Cureus,2018,10(4):e2536.
[13]李梅芳,杨瑜,陈道光,等.ICE方案挽救治疗52例复发难治性DLBCL的疗效及预后因素[J].肿瘤,2016,36(11):1376-1382.
[14]AMIN AD,PETERS TL,LI L,et al.Diffuse large B-cell lymphoma:can genomics improve treatment options for a curable cancer?[J]Cold Spring Harb Mol Case Stud,2017,3(3):a001719.
[15]CUBO AM,SOTO ZM,CRUZ MA,et al.Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone:A case report[J].Medicine(Baltimore),2017,96(19):e6846.
[16]YAMAMOTO M,WATANABE K,FUKUDAT,et al.Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy:A singleinstitution study[J].Anticancer Res,2017,37(5):2655-2662.
[17]LIU D,WU N,SUN H,et al.ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP[J].Oncotarget,2017,8(35):58292-58303.
[18]CHEN ZP,WEI JC,WANG Q,et al.Long noncoding RNA 00152 functions as a competing endogenous RNA to regulate NRP1 expression by sponging with mi RNA206 in colorectal cancer[J].Int JOncol,2018,53(3):1227-1236.
[19]JING N,HUANG T,GUO H,et al.LncRNACASC15 promotes colon cancer cell proliferation and metastasis by regulating the miR4310/LGR5/Wnt/β-catenin signaling pathway[J].Mol Med Rep,2018,18(2):2269-2276.
[20]GONG W,ZHENG J,LIU X,et al.Knockdown of long non-coding RNA KCNQ1OT1restrained glioma cells’malignancy by activating miR-370/CCNE2 axis[J].Front Cell Neurosci,2017,11:84.
[21]SUNAMURA N,OHIRA T,KATAOKA M,et al.Regulation of functional KCNQ1OT1 lnc RNA by beta-catenin[J].Sci Rep,2016,6:20690.
[22]LI C,MIAO R,ZHANG J,et al.Long noncoding RNA KCNQ1OT1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504[J].Int J Oncol,2018,3(13):122-127.